Medicine
Role of TERT promoter mutations in melanoma prognosis
Quick fact
Around 70% of melanomas harbor mutations in the TERT gene promoter, and these mutations are directly linked to worse overall survival, making them one of the most common and clinically significant genetic alterations in this cancer.
Why this is interesting
You’ve likely heard that sun exposure causes melanoma. But what if a single genetic switch—flipped on by the sun—could determine how aggressive that cancer becomes?
Read the full explanation
Understanding Role of TERT promoter mutations in melanoma prognosis
Think of the TERT gene as a blueprint for a protein that helps cells maintain their telomeres—the protective caps at the ends of chromosomes. Every time a cell divides, these caps shorten. If they get too short, the cell stops dividing. But in many cancers, including melanoma, mutations in the promoter region of the TERT gene cause the cell to produce more telomerase, the enzyme that rebuilds telomeres, effectively making the cell immortal. These mutations act like a stuck 'on' switch, keeping the telomerase production high. In melanoma, these mutations are particularly common and are strongly linked to how aggressive the tumor is. Patients whose cancers carry these mutations tend to have a worse prognosis—the cancer is more likely to spread and the patient survives for a shorter time. This is why TERT promoter status is now an important piece of information in the clinic.
A deeper explanation
The TERT gene encodes the catalytic subunit of telomerase. In healthy somatic cells, TERT expression is silenced, but in melanomas and many other cancers, it becomes reactivated. The most frequent mechanisms of reactivation are somatic point mutations in the TERT promoter, especially C228T and C250T. These mutations create de novo binding sites for the transcription factor E-twenty-six (ETS). ETS proteins, which are often activated by upstream signaling pathways, then bind to these sites and drive high-level TERT transcription. Chromatin remodeling also occurs at the mutant promoter, making the region more accessible to transcription machinery. From a prognostic standpoint, these mutations are associated with increased tumor aggressiveness, higher Breslow thickness, ulceration, and a higher risk of metastasis. Consequently, they are integrated into prognostic nomograms and even into the AJCC staging system. The presence of TERT promoter mutations is an independent marker of poorer survival in primary melanomas. Their high prevalence and clear biological mechanism make them a compelling target for future therapies, perhaps by blocking ETS binding or silencing the mutant promoter.